HER-2/neu expression and gene amplification in gastrinomas: Correlations with tumor biology, growth, and aggressiveness

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3702-3710

  Goebel, Stephan U ^a   Iwamoto, Michiko ^a   Raffeld, Mark ^b   Gibril, Fathia ^a   Hou, Wei ^a   Serrano, Jose ^a   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERCEPT; TRASTUZUMAB;

ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GASTRINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NEUROENDOCRINE TUMOR; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RNA ANALYSIS;

ADOLESCENT; ADULT; CELL DIVISION; FEMALE; GASTRINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENES, ERBB-2; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0036645056     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Natural history of digestive endocrine tumors
2. Natural history of neuroendocrine enteropancreatic tumors
3. Carcinoid tumors and the carcinoid syndrome
4. Prognostic factors in patients with endocrine tumors of the duodenopancreatic area
5. Benign and malignant gastrinoma
6. Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome
7. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study
8. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns
9. Pancreatic endocrine tumors
10. Oncogenes and rumor suppressor genes
11. Oncogenes and growth factors in thyroid carcinogenesis
12. Pancreatic endocrine tumors
13. Pancreatic endocrine tumors and carcinoid tumors: Recent insights from genetic and molecular biologic studies
14. Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours
15. Carcinoid and pancreatic endocrine rumors: Recent advances in molecular pathogenesis, localization, and treatment
16. Molecular insights in gastrointestinal neuroendocrine tumors: Importance and recent advances
17. Genotype/phenotype correlations of MENI gene mutations in sporadic gastrinoma
18. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors
19. Alterations in the p16 INK4a/CDKN2A tumor suppressor gene in gastrinomas
20. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: An analysis of p16/MTS1 tumor suppressor gene inactivation
21. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors
22. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
23. Her-2/neu and breast cancer
24. Basic science of HER-2/neu: A review
25. The HER-2/neu oncogene in tumors of the gastro-intestinal tract
26. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
27. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines
28. Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB
29. Oncoprotein immunoreactivity in human endocrine tumors
30. Analyses of MYC. ERBB2, and CCNDI genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction
31. Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas
32. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro
33. Oncoproteins and tumor progression in papillary thyroid carcinoma
34. Herceptin (trastuzamab) in advanced breast cancer
35. Therapy for pancreatic cancer with a recombinant humanized anti-HER-2 antibody (herceptin)
36. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
37. Oncogene expression in gastro-enteropancreatic neuroendocrine tumors: Implications for pathogenesis
38. Lack of C-erbB-2 protein expression in pulmonary carcinoid tumors
39. Overexpression of HER-2/neu in solid tumors: An immunohistochemical survey
40. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene
41. Amplification of the HER-2/neu protooncogene in human endocrine tumors
42. Endocrine neoplasms of the pancreas
43. Assessment and prediction of long-term cure in patients with Zollinger-Ellison syndrome: The best approach
44. Zollinger-Ellison syndrome: Clinical presentation in 261 patients
45. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1
46. Surgery to cure the Zollinger-Ellison syndrome
47. Detection of amplified oncogenes by differential polymerase chain reaction
48. Gastrinoma
49. Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome
50. Current approach to the management of tumoral process in patients with gastrinoma
51. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome
52. Gastric secretion in Zollinger-Ellison syndrome: Correlation with clinical expression, tumor extent and role in diagnosis: A prospective NIH study of 235 patients and review of the literature in 984 cases
53. Zollinger-Ellison syndrome
54. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
55. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
56. HER-2 overexpression, and intratumor heterogeneity in human breast cancer
57. C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors?
58. Detection of HER-2 oncogene amplification in breast cancer by differential polymerase chain reaction from single cryosections
59. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting
60. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease
61. Prognostic value of amplification of c-erb-B2 in bladder carcinoma
62. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplication
63. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
64. The c-erbB-2 proto-oncogene in human pancreatic cancer
65. HER-2 in prostate cancer - A viable target or innocent bystander?
66. Her2: The neu prognostic marker for breast cancer
67. Amplification of the c-erbB-2 gene in gastric carcinoma: Correlation with survival
68. p185HER-2 overexpression in human breast cancer using molecular and immunohistochemical methods
69. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer
70. Analysis of sporadic neuroendocrine tumors of the enteropancreatic system by comparative genomic hybridization
71. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system
72. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization
73. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids
74. The c-erbB-2/neu proto-oncogene in human pituitary tumours
75. Oncogene profile of papillary thyroid carcinoma
76. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
77. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
78. RNA and immunohistochemical characterization of the her-2/neu oncogene in transitional cell carcinoma of the bladder
79. C-erbb-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
80. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer
81. Value of topoisomerase II α. MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms
82. Demonstration of a TGF-α-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas
83. Oncogene expression in follicular neoplasms of the thyroid
84. Expression of bcl-2, c-erbB-2, p53, and p21 (wafl-cipl) protein in thyroid carcinomas
85. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas
86. Expression of c-erbB-2 protein in papillary thyroid carcinomas
87. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas
88. Her-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization
89. Prognostic significance of c-erbB-2 gene expression in the poorly differentiated type of adenocarcinoma of the stomach
90. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients
91. Prospective study of the natural history of gastrinoma in patients with MEN1: Definition of an aggressive and a nonaggressive form
92. Apparent lymph node primary gastrinoma